Effects of H. pylori eradication therapy on the Healing of Gastric ulcer after endoscopic mucosal resection/submucosal dissection

Effects of H. pylori eradication therapy on the Healing of Gastric ulcer after endoscopic mucosal resection/submucosal dissection - EMR/ESD HP eradication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009597

Enrollment

Registered

2013-01-01

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer

Interventions

H.pylori eradication therapy just after EMR/ESD. No H.pylori eradication therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who are going to undergo EMR/ESD due to early gastric cancer. Positive for Helicobacter pylori. Obtained Written informed consent.

Exclusion criteria

Exclusion criteria: Patients without H. pylori infection Patients with the history of gastric surgeries Patients with alarm symptoms such as vomiting, GI bleeding, rapid body weight loss Patients with alcohol/drug dependence Patients with severe endocrine problems Patients with severe injuries of heart, liver, kidney or bone marrow functions Patients with allergy against the test drugs Patients with pregnancy, possible pregnancy or breast feeding, or hope of pregnancy during the test period Patients whom the doctor decide as not proper for the study

Design outcomes

Primary

Measure	Time frame
The ratio of ulceration area after 4weeks and 16weeks of EMR/ESD compared with that of right after ESD	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026